J&J forecasts $2.5B COVID vaccine sales this year, lagging rivals

Johnson & Johnson revealed that it expects to take home about $2.5 billion from COVID-19 vaccine sales in 2021, far lower than estimates from its jab rivals Moderna and Pfizer.